Welcome to our dedicated page for Alcon news (Ticker: ALC), a resource for investors and traders seeking the latest updates and insights on Alcon stock.
Alcon Inc. (ALC) generates frequent news as a global eye care company listed on the SIX Swiss Exchange and the New York Stock Exchange. Company communications emphasize a long heritage in eye care, a broad Surgical and Vision Care portfolio, and a large international patient reach, which together make Alcon a regular subject of healthcare, medical device and capital markets coverage.
News about Alcon often highlights developments in its Surgical and Vision Care segments, including product launches and portfolio updates that address conditions such as cataracts, glaucoma, retinal diseases and refractive errors. The company has stated that it is advancing global launches of major products across these franchises, and such initiatives are typically announced through press releases and investor events.
Investors following ALC news can also expect updates on corporate strategy and transactions. For example, Alcon has reported on a definitive merger agreement with STAAR Surgical Company and later announced the termination of that agreement in a January 6, 2026 press release. These items appear in both company news and related regulatory filings, providing insight into how Alcon approaches acquisitions and refractive surgery strategy.
Coverage may further include Alcon’s participation in major healthcare conferences, where senior executives present the company’s outlook and discuss its Surgical and Vision Care businesses. Such events are typically accompanied by webcasts and formal announcements. By monitoring this news feed, readers can track key developments affecting Alcon’s product portfolio, strategic direction and presence in the global eye care market.
Summary not available.
Broadwood Partners (NASDAQ: STAA), which holds 27.5% of STAAR outstanding shares, sent a letter to STAAR Surgical’s board on October 17, 2025 urging directors to allow a timely shareholder vote on the proposed sale to Alcon (NYSE: ALC). Broadwood urges shareholders to vote AGAINST the acquisition announced August 5, 2025, arguing the board pursued a poorly designed process and an inadequate price.
Broadwood warns the board against delaying the October 23, 2025 vote or issuing misleading statements, and says shareholders and proxy advisors oppose the deal; it calls for the board to accept the vote result and work with shareholders if the transaction is rejected.
Summary not available.
Summary not available.
STAAR Surgical (NASDAQ: STAA) reiterated its board's unanimous recommendation that stockholders vote FOR the merger with Alcon on the white proxy card.
Key points: Alcon's offer is $28.00 per share in cash (a 59% premium to the 90-day VWAP). STAAR contrasts this with Broadwood's position and a prior price of $18.49 per share, warning a vote against could invite control shifts and valuation pressure. Stockholders are urged to contact STAAR's proxy solicitor for voting assistance.
Summary not available.
Defender Capital, a long-term shareholder owning approximately 1.5% of STAAR Surgical (NASDAQ: STAA), announced on October 7, 2025 its opposition to the proposed sale of STAAR to Alcon (NYSE: ALC) for $28 per share. Defender said the $28 price significantly undervalues STAAR, noting the STAAR board rejected a prior $58 per share cash offer from Alcon sixteen months earlier. Defender cited recent positive projections and outlook from STAAR management and argued there is no compelling reason to sell at the proposed valuation. Defender described the transaction as ill-advised and said it does not reflect STAAR’s standalone prospects.
Yunqi Capital (NASDAQ:STAA), a 5.1% shareholder, reiterated opposition to STAAR Surgical’s proposed sale to Alcon announced Aug 5, 2025, arguing the deal undervalues STAAR and mischaracterizes its China outlook.
Yunqi says recent revenue weakness (~10% decline 2023–2025) was driven by temporary China distributor inventory corrections (quarterly China revenue drops of 82%, 99%, 92% in late 2024–mid 2025) and that inventory has returned to historical levels per STAAR’s 10-Q. Yunqi highlights rising operating expenses (annualized run-rate from ~$150M in 2022 to ~$250M in 2024), U.S. headcount growth (~+400), and CEO merger-related payouts (~$24M of ~$55M total) as concerns. Yunqi proposes cost cuts, channel fixes and buybacks to unlock value instead of the sale.
Summary not available.
STAAR (NASDAQ: STAA) highlighted independent industry analyst commentary endorsing its proposed cash merger with Alcon at $28 per share. Analysts cite a ~59% premium to STAAR’s 90‑day VWAP, an implied total equity value of ~$1.5 billion and multiples ranging from ~4.7x FY26 sales to ~6x 2025 sales. STAAR warned of sustained standalone risks driven by severe China weakness (China revenue fell to $5.3M, -92% Y/Y) and channel inventory issues. The STAAR Board unanimously recommends voting “FOR” the merger at a special meeting on October 23, 2025.